Clinical Manifestation of Alopecia Areata After COVID-19 Infection or Vaccination
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Alopecia areata (AA) is characterized by an autoimmune inflammatory response to hair follicles. Several studies have suggested that infection and vaccination can trigger an autoimmune process around hair follicles. Moreover, reports of AA and various other autoim- mune diseases have increased since the coronavirus disease 2019 (COVID-19) pandemic became established. Objective: We assessed the clinical characteristics and treatment response in patients who developed AA following COVID-19 infection or vaccination. Methods: This retrospective study involved patients who had developed COVID-19 or received a COVID-19 vaccination within 3 months before the onset or aggravation of AA from January 2020 to December 2022. Results: Fifty patients met the inclusion criteria. Eighteen patients had a history of COVID-19 infection, and 32 had a history of COVID-19 vaccination. The mean onset of AA after COVID-19 infection and vaccination was 5.22±3.35 and 4.13±2.73 weeks, respectively. The most common COVID-19-associated symptoms before AA were fever (88.9%) in the infection group and myal- gia (50.0%) in the vaccination group. In the vaccination group, AA most commonly occurred after receiving the Pfizer-BioNTech vaccine (BNT162b2, 46.9%) or Moderna vaccine (mRNA- 1273, 34.4%). The vaccination group showed more rapid improvement than the infection group; however, both showed significant improvement after 6 months of treatment of AA. Conclusion: We examined the clinical characteristics and treatment responses of patients who developed AA after COVID-19 infection or vaccination. Further research is needed to evaluate the detailed pathogenesis and association between COVID-19 and AA.
Abstract
Background: Alopecia areata (AA) is characterized by an autoimmune inflammatory response to hair follicles. Several studies have suggested that infection and vaccination can trigger an autoimmune process around hair follicles. Moreover, reports of AA and various other autoim- mune diseases have increased since the coronavirus disease 2019 (COVID-19) pandemic became established. Objective: We assessed the clinical characteristics and treatment response in patients who developed AA following COVID-19 infection or vaccination. Methods: This retrospective study involved patients who had developed COVID-19 or received a COVID-19 vaccination within 3 months before the onset or aggravation of AA from January 2020 to December 2022. Results: Fifty patients met the inclusion criteria. Eighteen patients had a history of COVID-19 infection, and 32 had a history of COVID-19 vaccination. The mean onset of AA after COVID-19 infection and vaccination was 5.22±3.35 and 4.13±2.73 weeks, respectively. The most common COVID-19-associated symptoms before AA were fever (88.9%) in the infection group and myal- gia (50.0%) in the vaccination group. In the vaccination group, AA most commonly occurred after receiving the Pfizer-BioNTech vaccine (BNT162b2, 46.9%) or Moderna vaccine (mRNA- 1273, 34.4%). The vaccination group showed more rapid improvement than the infection group; however, both showed significant improvement after 6 months of treatment of AA. Conclusion: We examined the clinical characteristics and treatment responses of patients who developed AA after COVID-19 infection or vaccination. Further research is needed to evaluate the detailed pathogenesis and association between COVID-19 and AA.
참고문헌 (17)
- Ito T, "Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata", Exp Dermatol, 29, pp.726~732 (2020)
- Rajabi F, "Alopecia areata : a review of disease pathogenesis", Br J Dermatol, 179, pp.1033~1048 (2018)
- Richardson CT, "Evaluation of the relationship between alopecia areata and viral antigen exposure", Am J Clin Dermatol, 19, pp.119~126 (2018)
- Rodríguez Y, "Autoinflammatory and autoimmune conditions at the crossroad of COVID-19", J Autoimmun, 114, pp.102506~ (2020)
- Chen Y, "New-onset autoimmune phenomena post-COVID-19 vaccination", Immunology, 165, pp.386~401 (2022)
- Birkett L, "Possible associations between alopecia areata and COVID-19 vaccination and infection", Aesthet Surg J, 42, pp.NP699~NP702 (2022)
- Rossi A, "Recurrence of alopecia areata after covid-19 vaccination : a report of three cases in Italy", J Cosmet Dermatol, 20, pp.3753~3757 (2021)
- May Lee M, "Alopecia areata following COVID-19 vaccination : vaccine-induced autoimmunity", Int J Dermatol, 61, pp.634~635 (2022)
- Nguyen B, "Alopecia areata after COVID-19 infection and vac¬cination : a cross-sectional analysis", J Eur Acad Dermatol Venereol, 37, pp.e7~e8 (2023)
- Christensen RE, "Association between alopecia areata and COVID-19 : a systematic review", JAAD Int, 7, pp.57~61 (2022)
- Olsen EA, "Alopecia areata investigational assessment guidelines--Part II", J Am Acad Dermatol, 51, pp.440~447 (2004)
- Kostopoulos-Kanitakis KA, "Skin diseases associated with COVID-19 : a narrative review", Cutis, 111, pp.E19~E27 (2023)
- Toussi A, "Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata : a systematic review", J Am Acad Dermatol, 85, pp.162~175 (2021)
- Shimabukuro-Vornhagen A, "Cytokine release syndrome", J Immunother Cancer, 6, pp.56~ (2018)
- Tan Y, "SARS-CoV-2-mediated immune system activation and potential application in immunotherapy", Med Res Rev, 41, pp.1167~1194 (2021)
- Adiguzel Y, "Molecular mimicry between SARS-CoV-2 and human proteins", Autoimmun Rev, 20, pp.102791~ (2021)
- Kovačić D, "The possible role of molecular mimicry in SARS-CoV-2-mediated autoimmunity : an immunobiochemical basis", J Med Sci, 90, pp.e560~ (2021)